Glucagon Nasenspray: Peptide Product for Severe Hypoglycemia
This data-driven analysis explores glucagon nasal spray, a synthetic 29‑amino‑acid peptide rescue therapy for severe hypoglycemia. The global glucagon market ( $457M in 2023) grows at 7.9% CAGR. Brand comparison of Baqsimi (FDA 2019), generics and Gvoke injection reveals technical pros/cons: Baqsimi’s 3 mg powder device needs no reconstitution, achieves 98.7% success within 30 min, ships ambient, yet costs more. Peptide identity matches native glucagon. The review covers product parameters (24‑month shelf life), GMP factory qualifications, and regulatory certificates. Selection guidance emphasizes device reliability, real‑world data, and cold‑chain‑free logistics. Market trends, clinical evidence, and peptide industry outlook are synthesized.